How should a patient with pseudoxanthoma elasticum be clinically evaluated and managed?

Clinical Evaluation and Management of Pseudoxanthoma Elasticum

Patients with pseudoxanthoma elasticum require systematic multidisciplinary screening at diagnosis and regular surveillance for cardiovascular, ophthalmologic, and dermatologic complications, with management focused on preventing vision loss through anti-VEGF therapy for choroidal neovascularization and addressing cardiovascular disease risk. 1

Initial Diagnostic Evaluation

The diagnosis of PXE requires three key components working together:

• Dermatologic examination: Look for characteristic yellow papules on the neck and flexural areas (axillae, antecubital fossae, groin) that coalesce into redundant, lax skin folds 2, 3
• Skin biopsy: Confirm accumulation of pleiomorphic elastic structures in the mid-to-deep dermis with progressive mineralization 2
• Genetic testing: Identify mutations in the ABCC6 gene (autosomal recessive inheritance) 4, 3

The dermatologist plays a crucial role as the initial diagnostic gatekeeper, since skin changes are often the first recognized manifestation 5.

Mandatory Baseline Screening

Once PXE is diagnosed, immediately arrange comprehensive organ system evaluation:

Ophthalmologic Assessment

• Dilated fundus examination for peau d'orange (mottled appearance of posterior pole), angioid streaks (breaks in calcified Bruch's membrane), and comet tail lesions 6, 3
• Optical coherence tomography (OCT) to detect early choroidal neovascularization
• This is critical because vision loss from secondary macular neovascularization is a major cause of morbidity 6, 7

Cardiovascular Evaluation

• Blood pressure monitoring for hypertension
• Peripheral arterial assessment including ankle-brachial index, as PXE causes small-to-medium artery calcification leading to peripheral arterial disease 4, 8
• Screening for premature coronary artery disease and cerebrovascular disease risk 8
• Renal artery evaluation if hypertension is present (renal artery stenosis occurs) 4
• Consider gastrointestinal symptoms (early satiety, cramping) as vascular involvement can affect mesenteric vessels 8

Ongoing Management Strategy

Ophthalmologic Management (Highest Priority for Quality of Life)

Treat choroidal neovascularization immediately with intravitreal anti-VEGF injections - this is the only established effective therapy for preventing vision loss 6, 7. Alternative treatments (laser photocoagulation, photodynamic therapy, macular translocation surgery) are available but anti-VEGF is now standard 6.

• Schedule ophthalmologic follow-up every 6-12 months, or more frequently if neovascularization develops 1

Cardiovascular Risk Reduction

• Aggressive cardiovascular risk factor modification: smoking cessation is essential, as smoking accelerates arterial disease 2
• Manage hypertension, hyperlipidemia, and diabetes aggressively given the underlying arteriopathy 4
• Monitor for stroke risk - PXE causes both large- and small-artery disease 4

Dietary and Lifestyle Interventions

Evidence from murine models suggests dietary magnesium content may influence mineralization severity 2. While no definitive human trials exist, appropriate dietary interventions coupled with lifestyle modifications (particularly smoking cessation) may alleviate symptoms 2.

Dermatologic Management

• Skin lesions themselves require no specific treatment unless causing functional or significant psychological distress
• Surgical excision and skin tightening procedures (cervicofacial facelifts, brachioplasties, cruroplasties) can be offered for excess redundant skin with good aesthetic and functional outcomes 9
• Patients heal normally without increased complication risk 9

Critical Pitfalls to Avoid

• Do not delay ophthalmologic referral - vision loss from untreated neovascularization is preventable with anti-VEGF therapy
• Do not underestimate cardiovascular risk - these patients develop premature arterial disease affecting coronary, cerebral, peripheral, and renal circulations 4, 8
• Do not miss the diagnosis in childhood - PXE can present early and benefits from early recognition for timely intervention 10
• Do not forget genetic counseling - this is autosomal recessive; family screening may identify additional affected individuals 10

Emerging Therapies

While no causative treatment currently exists, clinical trials targeting ectopic mineralization are emerging 7, 3. Refer patients to specialized PXE centers for potential trial enrollment and expert management 7. The pathophysiology involves low plasma inorganic pyrophosphate (PPi) due to ABCC6 mutations, and therapeutic approaches aim to address this deficiency 3.

The estimated prevalence is 1:25,000 to 1:100,000, making this a rare disease requiring specialized expertise 4.